This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.

DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

Medtronic PLC investors have been content with receiving dividends on their holdings for a few years now. The stock has ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to ...

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...

Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of ...

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson’s rating is ...

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...

Medtronic announced today that it received CE mark approval for its Evolut FX+ transcatheter aortic valve implantation (TAVI) ...